An interventional study of Sacral neuromodulation in Urge Incontinence, Urgency-frequency Syndrome and Overactive Bladder, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by University of Chicago · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 30th largest by planned enrollment of the 119 interventional ones that give a count, is one of 7 that started in 2023, is one of 72 with no phase, reaches primary completion later than 15 of the 25 other live ones, and was the 118th registered.
243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.
Browse Urinary Incontinence, Urge studies →19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18–89
Axonics, Inc. · Sites in United States, Australia
Ages 18+
Neuspera Medical, Inc. · Sites in United States
Ages 22+
MedtronicNeuro · Sites in United States
Ages 18+
InMode MD Ltd. · Sites in United States
Ages 22–80 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 14 · Phase 4 19
First in 2003; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 193 is above the median of 86 across 191 interventional studies indexed under Urinary Incontinence, Urge.
Median enrollment 75 across the 119 interventional studies, 47 across the 15 observational. Of the 97 that completed or were terminated, 51 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 135 have an industry lead sponsor. The 10 most frequent:
University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.
Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.
University of Chicago has 1 study filed under Urinary Incontinence, Urge — fewer than ten, so there is no comparison to draw.
11 of the studies in Urinary Incontinence, Urge with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06797245Medstar Health Research InstituteAPPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women | 2026-11 |
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT07335484Axonics, Inc.Aquarius Pilot Study to Evaluate the New Axonics Trial System | 2026-11 |
| NCT07247136Neuspera Medical, Inc.Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System | 2026-11 |
| NCT06186765Axonics, Inc.F15 Recharge Free Axonics SNM System Clinical Study | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998. One of two trial phase techniques are utilized prior to placement of the implantable pulse generator (IPG) to predict a patient's success with the device: a percutaneous nerve evaluation (PNE) or a stage implantation. Patients who experience a > 50% improvement in UUI symptoms progress to permanent implantation. PNE offers significant advantages compared to a staged implantation including a single anesthetic and operating room trip. Historically, full implantation rates are only 40-50% following PNE versus 70-90% in women who undergo a staged approach. The lower rate of progression to full implantation after PNE may be attributed to lead migration. Newer data suggest up to 90% of PNE trials lead to full implantation. The investigators hypothesize that shortening PNE trial time to 3 days from 7 days will not result in a lower proportion of PNE trials leading to SNM implantation and may offer less time for lead migration. The investigators aim to perform a multi-center, randomized trial to determine if a 3-day PNE trial is not inferior to a 7-day PNE trial with respect to rates of progression to SNM implantation.
Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. It is FDA-approved for the treatment of urgency urinary incontinence (UUI) refractory to behavioral modifications and/or oral medication. The efficacy of SNM for the treatment of UUI is well studied and currently, there are two manufacturers of SNM devices within the United States: Medtronic and Axonics. Both offer rechargeable and non-rechargeable devices.
Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as >50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room. The staged approach involves two separate procedures performed in the operating room: stage I and stage II. Stage I is the clinical trial of the permanent lead with electrodes using external stimulation. Following adequate response, stage II is performed and involves the IPG placement.
PNE offers significant advantages compared to a staged implantation. A PNE is performed in the office under local anesthesia mitigating the anesthetic risk and number of operating room visits. PNE is also suspected to be cost-effective given it is performed in the office with minimal medical equipment; however, this has not been well studied. Full implantation rates are 40-50% following PNE versus 70-90% in women who undergo a staged approach. The lower rate of progression to full implantation with PNE can be attributed to several factors including lead migration. The monopolar PNE lead does not have a self-retaining component like the quadripolar tined lead used during a stage approach. Newer registry data suggest up to 90% of PNE trials lead to full implantation. Authors hypothesize the improved full implantation rates in the newer studies may be secondary to shorter trial times and improved anatomic knowledge.
The trial phase is the most valuable tool to predict therapeutic success of SNM for women with UUI. Several large, multicenter trials support that PNE and staged trial can predict patients who are likely to respond to SNM therapy and experience long term benefits. Literature is limited regarding recommended length of time for the trial phase. The International Continence Society best practice statement for use of SNM currently recommends 7-day trial for women with UUI. However, one study reported high sensitivity and specificity of PNE with a trial time of 3-5 days. This cross-sectional study was limited to a single institution and included patients with nonobstructive urinary retention.
Given the risk of lead migration with PNE, the investigators hypothesize that shortening the trial phase to 3 days will not decrease the proportion of patients who progress onto full SNM implantation. The investigators believe that shortening the window to capture therapeutic response will have several important patient benefits and reduce the chance of lead migration without adversely impacting outcomes. Therefore, the investigators aim to perform a multi-center, randomized trial to determine if a 3-day PNE trial is not inferior to a 7-day PNE trial with respect to rates of progression to full SNM implantation.
The investigators plan to perform a multi-center, randomized, non-inferiority trial of patients receiving SNM for UUI or urgency-frequency syndrome (UF) who elect to undergo a PNE. Informed consent will be obtained for participants who meet eligibility criteria. Participants will be computer randomized in a 1:1 fashion to either a 3 or 7-day PNE trial on the day of PNE (to minimize bias and drop out). Permuted blocks will be utilized with a fixed block size stratified by age (\<65 versus >65 years old) and study site. Decision to stratify by age is based on the association between advancing age and decreased SNM response. Patients must have at least 5 episodes of UUI or at least 8 voids per day for 2 days on a 3-day bladder diary to be included. Demographic and symptom data will be collected at participants baseline visit including a 3-day bladder diary and validated patient reported outcome measures for urinary symptoms and quality of life (Urinary Distress Inventory, Lower Urinary Tract Dysfunction Research Network Symptom Index-10, Incontinence Impact Questionnaire). At the PNE visit and PNE removal, clinical information will be recorded, and patient reported outcome measures will be repeated (including Patient Global Impression of Improvement). Patients who have an adequate response to PNE placement (>50% improvement in UUI/UF symptoms determined by 3-day bladder diary) will progress to full SNM implantation.
Assuming a significance level of 5% and 80% rate of progression to full implantation in each arm with a noninferiority margin of 15 percentage points, the investigators calculate that 88 women would need to enroll in each study arm to have 80% power for determining whether the results in the 3-day PNE trial arm are noninferior to those in the 7-day trial arm. The investigators propose a 15% noninferiority margin on the basis of clinical judgement that this is a reasonable tradeoff between a decrease in progression to full or stage implantation and the possibility of shortening the PNE trial period. Assuming a 10% dropout rate, a total sample of 193 women will be required. Non-inferiority will be declared if the upper bound of the 95% confidence interval for the rate of progression to full implantation between groups is less than 15%. To minimize bias toward noninferiority, only women treated per protocol will be considered in the primary outcome analysis.
De-identified data will be collected at each site in a REDCap database then transferred to an SPSS database (IBM SPSS Statistics for Macintosh, Version 22.0. Armonk, NY: IBM Corp) for statistical analysis. Secondary outcomes will be assessed using intent to treat analyses.
Comparative statistics for patient demographics and clinical outcomes will be performed between the two cohorts utilizing chi-square, t-test, and Wilcoxon test as appropriate for continuous and categorical variables. Logistic regression models will be used to evaluate the association between factors and rate of full SNM implantation following PNE. Multivariate logistic regression to control for potential cofounding variables.
The investigators estimate being able to recruit 3 women undergoing PNE each month during the study period from the investigator's site or 36 participants in 1-year. Given the standard of care is a 7-day PNE, the investigators anticipate patients will be eager for the option to be randomized to a less onerous test period. In addition, the only patient burden (beyond standard of care) is completion of a series of validated questionnaires, which the investigators estimate will take 15 minutes at both time points. There are currently two SNM device manufacturers (Medtronic and Axonics) as well as a national-reported increased in SNM implantation procedures over the past decade.15 While there are no comparative date between these devices, the investigators think both can be included in this trial to increase generalizability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the 3-day trial arm will undergo a 3-day PNE trial phase for sacral neuromodulation. Participants will have the PNE placed in the office and return on day 3 for PNE removal.
Procedure: Sacral neuromodulation
Patients randomized to the73-day trial arm will undergo a 7-day PNE trial time for sacral neuromodulation. Participants will have the PNE placed in the office and return on day 7 for PNE removal.
Procedure: Sacral neuromodulation
Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as \>50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.
Also known as: Percutaneous nerve evaluation
Rate of progression onto full sacral neuomodulation (SNM) implant
Participants with an adequate therapeutic response during percutaneous nerve evaluation (PNE) trial (\>/=50% improvement in urgency urinary incontinence (UUI)/ urgency-frequency (UF) symptoms) will progress onto full SNM implantation
Time frame: 3 or 7 days depending on treatment arm
Patient satisfaction
Participants will complete validated patient reported outcome measures at baseline and at PNE lead pull
Time frame: 3 or 7 days depending on treatment arm
Rate of adverse events
Adverse events during trial phase will be recorded
Time frame: 3 or 7 days depending on treatment arm
Quality of life scores
Participants will complete validated patient reported outcome measures at baseline and at PNE lead pull
Time frame: 3 or 7 days depending on treatment arm
Plan to share: No
Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.
Of 47 non-industry interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 36 months is above that.
Counting every sponsor, half of 77 studies reached it within 20 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.